Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
PitNET
acromegaly
cytokeratin 18
internexin-α
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
02
03
2021
received:
08
02
2021
accepted:
16
03
2021
pubmed:
20
3
2021
medline:
21
12
2021
entrez:
19
3
2021
Statut:
ppublish
Résumé
In somatotroph pituitary neuroendocrine tumours (adenomas), a pattern of cytokeratin (CK) 18 expression is used for tumour subclassification, with possible clinical implications. Rare somatotroph tumours do not express CK 18. We aimed to characterise this subset clinically and histologically. Clinical and pathological data for the study were derived from a previously published data set of a cohort of 110 patients with acromegaly. Data included serum levels of insulin-like growth factor 1 (IGF1), growth hormone (GH), prolactin and thyroid-stimulating hormone (TSH), tumour diameter, tumour invasion defined by Knosp grade and immunohistochemical data concerning the expression of Ki67, p53, E-cadherin, somatostatin receptor (SSTR)1, SSTR2A, SSTR3, SSTR5 and D2 dopamine receptor. Additional immunohistochemical analysis (AE1/3, CK 8/18, vimentin, neurofilament light chain, internexin-α) was performed. CK 18 was negative in 10 of 110 (9.1%) tumours. One of these tumours was immunoreactive with CK 8/18 antibody, while the remainder expressed only internexin-α intermediate filament in patterns similar to CK 18 (perinuclear fibrous bodies). CK-negative tumours showed no significant differences with respect to biochemical, radiological or pathological features. They showed significantly higher expression of SSTR2A compared to the sparsely granulated subtype and significantly lower expression of E-cadherin compared to the non-sparsely granulated subtypes of tumours. The tumours showed divergent morphology and hormonal expression: two corresponded to densely granulated tumours and three showed co-expression of prolactin and morphology of either mammosomatotroph or somatotroph-lactotroph tumours. Four tumours showed morphology and immunoprofile compatible with plurihormonal Pit1-positive tumours. CK-negative somatotroph tumours do not represent a distinct subtype of somatotroph tumours, and can be further subdivided according to their morphology and immunoprofile.
Substances chimiques
Biomarkers, Tumor
0
Keratin-8
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
406-415Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : NV19-01-00435
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Duan K, Mete O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: practical applications of immunohistochemical markers. Cancer Cytopathol. 2016; 124(12): 871-884. http://doi.org/10.1002/cncy.21765
Villa C, Vasiljevic A, Jaffrain-Rea ML et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (pitnets): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch 2019; 475(6); 687-692.
Coons SW, Estrada SI, Gamez R, White WL. Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr. Pathol. 2005; 16; 201-210.
Hsu JD, Yao CC, Han LW, Han CP. CAM5.2 is not identical to cytokeratins 8 and 18. Am. J. Clin. Pathol. 2010; 133(3); 514.
Kleinschmidt-DeMasters BK, Lopes MB, Prayson RA. An algorithmic approach to sellar region masses. Arch. Pathol. Lab. Med. 2015; 139; 356-372.
Syro LV, Rotondo F, Serna CA, Ortiz LD, Kovacs K. Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary 2017; 20; 84-92.
Obari A, Sano T, Ohyama K et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 2008; 19; 82-91.
Bakhtiar Y, Hirano H, Arita K et al. Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 2010; 163; 531-539.
Chinezu L, Vasiljevic A, Jouanneau E et al. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum. Pathol. 2014; 45; 71-77.
Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 2013; 16; 490-498.
Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. (Oxf) 2012; 76; 96-102.
Mori R, Inoshita N, Takahashi-Fujigasaki J et al. Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol. 2013; 2013; 723432.
Chinezu L, Jouanneau E, Vasiljevic A, Trouillas J, Raverot G. Silent GH pituitary tumor: diagnostic and therapeutic challenges. Ann. Endocrinol. (Paris) 2013; 74; 491-495.
Iacovazzo D, Carlsen E, Lugli F et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 2016; 174; 241-250.
Venegas-Moreno E, Flores-Martinez A, Dios E et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J. Cell. Mol. Med. 2019; 23; 3088-3096.
Soukup J, Česák T, Hornychová H et al. Stem cell transcription factor SOX2 is expressed in a subset of folliculo-stellate cells of growth hormone-producing pituitary neuroendocrine tumours and its expression shows no association with tumour size or IGF1 levels: a clinicopathological study of 109 cases. Endocr. Pathol. 2020; 31; 337-347.
Soukup J, Hornychova H, Manethova M et al. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. J. Cell. Mol. Med. 2021; 25(5); 2484-2492.
Trouillas J, Roy P, Sturm N et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013; 126; 123-135.
Quinlan RA, Schiller DL, Hatzfeld M et al. Patterns of expression and organization of cytokeratin intermediate filaments. Ann N Y Acad Sci 1985; 455; 282-306.
Mete O, Kefeli M, Caliskan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod. Pathol. 2019; 32; 484-489.
Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds.), World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer. 2017; 355.
Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod. Pathol. 2018; 31; 900-909.
Xu B, Sano T, Yoshimoto K, Yamada S. Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr. Pathol. 2002; 13; 341-351.
Neou M, Villa C, Armignacco R et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 2020; 37(1); 123-134.e5.
Mete O, Gomez-Hernandez K, Kucharczyk W et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal pit-1 lineage adenomas. Mod. Pathol. 2016; 29; 131-142.
Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol. Metab. 2010; 21; 123-133.
Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin. Endocrinol. (Oxf) 2008; 68; 458-465.
Schult D, Holsken A, Buchfelder M et al. Expression pattern of neuronal intermediate filament alpha-internexin in anterior pituitary gland and related tumors. Pituitary 2015; 18; 465-473.
Lopes MB, Sloan E, Polder J. Mixed gangliocytoma-pituitary adenoma: insights on the pathogenesis of a rare sellar tumor. Am. J. Surg. Pathol. 2017; 41; 586-595.
Kontogeorgos G, Mourouti G, Kyrodimou E, Liapi-Avgeri G, Parasi E. Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells. Acta Neuropathol. 2006; 112; 21-28.
Asa SL, Mete O. Cytokeratin profiles in pituitary neuroendocrine tumors. Hum. Pathol. 2021; 107: 87-95.
Wang Y, Chen Y, Li X et al. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm. BMC Cancer 2018; 18; 691.
Chauvet N, Romanò N, Meunier A-C et al. Combining cadherin expression with molecular markers discriminates invasiveness in growth hormone and prolactin pituitary adenomas. J. Neuroendocrinol. 2016; 28; 12352.
Lekva T, Berg JP, Fougner SL, Olstad OK, Ueland T, Bollerslev J. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J. Clin. Endocrinol. Metab. 2012; 97; E1506-E1514.
Barry S, Carlsen E, Marques P et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene 2019; 38; 5381-5395.
Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin. Exp. Metastasis 2008; 25; 621-628.